232 related articles for article (PubMed ID: 28068312)
1. MraY-antibiotic complex reveals details of tunicamycin mode of action.
Hakulinen JK; Hering J; Brändén G; Chen H; Snijder A; Ek M; Johansson P
Nat Chem Biol; 2017 Mar; 13(3):265-267. PubMed ID: 28068312
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of a MraY selective analogue of tunicamycins.
Yamamoto K; Sato T; Hikiji Y; Katsuyama A; Matsumaru T; Yakushiji F; Yokota SI; Ichikawa S
Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):349-364. PubMed ID: 31566068
[TBL] [Abstract][Full Text] [Related]
3. Exploring the Active Site of the Antibacterial Target MraY by Modified Tunicamycins.
Hering J; Dunevall E; Snijder A; Eriksson PO; Jackson MA; Hartman TM; Ting R; Chen H; Price NPJ; Brändén G; Ek M
ACS Chem Biol; 2020 Nov; 15(11):2885-2895. PubMed ID: 33164499
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for selective inhibition of antibacterial target MraY, a membrane-bound enzyme involved in peptidoglycan synthesis.
Hering J; Dunevall E; Ek M; Brändén G
Drug Discov Today; 2018 Jul; 23(7):1426-1435. PubMed ID: 29778697
[TBL] [Abstract][Full Text] [Related]
5. Structural insights into inhibition of lipid I production in bacterial cell wall synthesis.
Chung BC; Mashalidis EH; Tanino T; Kim M; Matsuda A; Hong J; Ichikawa S; Lee SY
Nature; 2016 May; 533(7604):557-560. PubMed ID: 27088606
[TBL] [Abstract][Full Text] [Related]
6. GlcNAc-1-P-transferase-tunicamycin complex structure reveals basis for inhibition of N-glycosylation.
Yoo J; Mashalidis EH; Kuk ACY; Yamamoto K; Kaeser B; Ichikawa S; Lee SY
Nat Struct Mol Biol; 2018 Mar; 25(3):217-224. PubMed ID: 29459785
[TBL] [Abstract][Full Text] [Related]
7. Phospho-MurNAc-pentapeptide translocase (MraY) as a target for antibacterial agents and antibacterial proteins.
Bugg TD; Lloyd AJ; Roper DI
Infect Disord Drug Targets; 2006 Jun; 6(2):85-106. PubMed ID: 16789873
[TBL] [Abstract][Full Text] [Related]
8. Structures of Bacterial MraY and Human GPT Provide Insights into Rational Antibiotic Design.
Mashalidis EH; Lee SY
J Mol Biol; 2020 Aug; 432(18):4946-4963. PubMed ID: 32199982
[TBL] [Abstract][Full Text] [Related]
9. [Bridge between Total Synthesis of Bioactive Natural Products and Development of Drug Leads].
Ichikawa S
Yakugaku Zasshi; 2022; 142(4):355-363. PubMed ID: 35370192
[TBL] [Abstract][Full Text] [Related]
10. The Escherichia coli mraY gene encoding UDP-N-acetylmuramoyl-pentapeptide: undecaprenyl-phosphate phospho-N-acetylmuramoyl-pentapeptide transferase.
Ikeda M; Wachi M; Jung HK; Ishino F; Matsuhashi M
J Bacteriol; 1991 Feb; 173(3):1021-6. PubMed ID: 1846850
[TBL] [Abstract][Full Text] [Related]
11. New Insight into the Catalytic Mechanism of Bacterial MraY from Enzyme Kinetics and Docking Studies.
Liu Y; Rodrigues JP; Bonvin AM; Zaal EA; Berkers CR; Heger M; Gawarecka K; Swiezewska E; Breukink E; Egmond MR
J Biol Chem; 2016 Jul; 291(29):15057-68. PubMed ID: 27226570
[TBL] [Abstract][Full Text] [Related]
12. Purification and characterization of the bacterial MraY translocase catalyzing the first membrane step of peptidoglycan biosynthesis.
Bouhss A; Crouvoisier M; Blanot D; Mengin-Lecreulx D
J Biol Chem; 2004 Jul; 279(29):29974-80. PubMed ID: 15131133
[TBL] [Abstract][Full Text] [Related]
13. Antibacterial Nucleoside Natural Products Inhibiting Phospho-MurNAc-Pentapeptide Translocase; Chemistry and Structure-Activity Relationship.
Ichikawa S; Yamaguchi M; Matsuda A
Curr Med Chem; 2015; 22(34):3951-79. PubMed ID: 26282943
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel inhibitors of phospho-MurNAc-pentapeptide translocase MraY from library screening: Isoquinoline alkaloid michellamine B and xanthene dye phloxine B.
Mihalyi A; Jamshidi S; Slikas J; Bugg TD
Bioorg Med Chem; 2014 Sep; 22(17):4566-71. PubMed ID: 25127465
[TBL] [Abstract][Full Text] [Related]
15. Caprazamycins: Promising lead structures acting on a novel antibacterial target MraY.
Patel B; Ryan P; Makwana V; Zunk M; Rudrawar S; Grant G
Eur J Med Chem; 2019 Jun; 171():462-474. PubMed ID: 30933853
[TBL] [Abstract][Full Text] [Related]
16. Caprazamycins: Biosynthesis and structure activity relationship studies.
Wiker F; Hauck N; Grond S; Gust B
Int J Med Microbiol; 2019 Jul; 309(5):319-324. PubMed ID: 31138496
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of cyclopentane-based muraymycin analogs targeting MraY.
Kwak SH; Lim WY; Hao A; Mashalidis EH; Kwon DY; Jeong P; Kim MJ; Lee SY; Hong J
Eur J Med Chem; 2021 Apr; 215():113272. PubMed ID: 33607457
[TBL] [Abstract][Full Text] [Related]
18. Liposidomycin, the first reported nucleoside antibiotic inhibitor of peptidoglycan biosynthesis translocase I: The discovery of liposidomycin and related compounds with a perspective on their application to new antibiotics.
Kimura KI
J Antibiot (Tokyo); 2019 Dec; 72(12):877-889. PubMed ID: 31582803
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of phospho-MurNAc-pentapeptide translocase (MraY) by nucleoside natural product antibiotics, bacteriophage ϕX174 lysis protein E, and cationic antibacterial peptides.
Bugg TD; Rodolis MT; Mihalyi A; Jamshidi S
Bioorg Med Chem; 2016 Dec; 24(24):6340-6347. PubMed ID: 27021004
[TBL] [Abstract][Full Text] [Related]
20. Interaction of the transmembrane domain of lysis protein E from bacteriophage phiX174 with bacterial translocase MraY and peptidyl-prolyl isomerase SlyD.
Mendel S; Holbourn JM; Schouten JA; Bugg TDH
Microbiology (Reading); 2006 Oct; 152(Pt 10):2959-2967. PubMed ID: 17005977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
